Fabry disease: enzymatic screening using dried blood spots on filter paper

被引:10
作者
Caudron, E. [1 ]
Germain, D. P. [2 ,3 ]
Prognon, P. [1 ]
机构
[1] Fac Pharm Paris XI, Grp Chim Analyt Paris Sud, EA 4041, F-92290 Chatenay Malabry, France
[2] Hop Raymond Poincare, AP HP, Ctr Reference Malad Fabry & Malad Hereditaires Ti, UF Genet Med, F-92380 Garches, France
[3] Univ Versailles St Quentin Yvelines, F-72035 Versailles, France
来源
REVUE DE MEDECINE INTERNE | 2010年 / 31卷
关键词
Fabry disease; alpha-galactosidase A; Dried blood spot; Filter paper; Screening test; REPLACEMENT THERAPY; ALPHA-GALACTOSIDASE; REGISTRY; COHORT; IDENTIFICATION; POPULATIONS; PREVALENCE; DIAGNOSIS; EFFICACY; FEMALES;
D O I
10.1016/S0248-8663(10)70025-4
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Introduction - Fabry disease (FD) is an X-linked lysosomal storage disorder caused by mutations in the CIA gene, which leads to a deficient activity of a-galactosidase A. a-galactosidase A activity can be assayed on dried blood spots on filter paper but the original method has been associated with a number of false positive due in great part to quenching of fluorescence. Here, we describe an adaptation of the original fluorimetric method reducing quenching of the fluorescence. Results - A simple and sensitive fluorimetric method has been described for the determination of the a-galactosidase A activity in dried blood spots on filter paper, convenient for screening of FD in at-risk populations. The procedure uses 4-methylumbelliferyl-alpha-D-galactose, as a synthetic substrate for the enzyme. In this study, protein precipitation was added after incubation both to stop the enzymatic reaction and eliminate interfering proteins. With the novel method the risk of false-positive due to fluorescence quenching was minimized. A cut-off level of 2.1 mu mol.h(-1).L-1 (control values: 5.6 +/- 2.0 mu mol.h(-1).L-1, mean +/- SD) was chosen corresponding to 40 % of median control value. In all 60 hemizygotes males, a-gal A activities were below 1.1 mu mol.h(-1).L-1 (0.11 +/- 0.2 mu mol.h(-1).L-1). In the 68 heterozygous females, a-gal A activity ranged from 0 to 7.8 mu mol.h(-1).L-1 (2.2 +/- 1.7 mu mol.h(-1).L-1). Using the improved methodology, one third of the females were not identified using the enzymatic assay, due to significant residual enzyme activity. Conclusion - This improved method for the assay of a-gal A was robust and reduced the number of false-positive results. It can be applied for the screening of at-risk populations. a-galactosidase A enzymatic assay should not be used for screening for FD in women or, if used, should be interpreted cautiously together with the results of genotyping. (C) 2010 Societe nationale francaise de medecine interne (SNFMI). Published by Elsevier Masson SAS. All rights reserved.
引用
收藏
页码:S263 / S269
页数:7
相关论文
共 23 条
[1]   Belgian Fabry Study Prevalence of Fabry Disease in a Cohort of 1000 Young Patients With Cerebrovascular Disease [J].
Brouns, Raf ;
Thijs, Vincent ;
Eyskens, Francois ;
Van den Broeck, Marleen ;
Belachew, Shibeshih ;
Van Broeckhoven, Christine ;
Redondo, Patricia ;
Hemelsoet, Dimitri ;
Fumal, Arnaud ;
Jeangette, Sandrine ;
Verslegers, Werner ;
Baker, Robert ;
Hughes, Derralynn ;
De Deyn, Peter Paul .
STROKE, 2010, 41 (05) :863-868
[2]   Recent advances of Fabry disease screening for at risk population [J].
Caudron, É ;
Molière, D ;
Zhou, JY ;
Prognon, P ;
Germain, DP .
M S-MEDECINE SCIENCES, 2005, 21 :48-50
[3]   Fabry disease: enzymatic diagnosis in dried blood spots on filter paper [J].
Chamoles, NA ;
Blanco, M ;
Gaggioli, D .
CLINICA CHIMICA ACTA, 2001, 308 (1-2) :195-196
[4]  
DESNICK RJ, 1973, J LAB CLIN MED, V81, P157
[5]   Fabry disease: Baseline medical characteristics of a cohort of 1765 males and females in the Fabry Registry [J].
Eng, C. M. ;
Fletcher, J. ;
Wilcox, W. R. ;
Waldek, S. ;
Scott, C. R. ;
Sillence, D. O. ;
Breunig, F. ;
Charrow, J. ;
Germain, D. P. ;
Nicholls, K. ;
Banikazemi, M. .
JOURNAL OF INHERITED METABOLIC DISEASE, 2007, 30 (02) :184-192
[6]   Safety and efficacy of recombinant human α-galactosidase a replacement therapy in Fabry's disease. [J].
Eng, CM ;
Guffon, N ;
Wilcox, WR ;
Germain, DP ;
Lee, P ;
Waldek, S ;
Caplan, L ;
Linthorst, GE ;
Desnick, RJ .
NEW ENGLAND JOURNAL OF MEDICINE, 2001, 345 (01) :9-16
[7]   Fabry disease: The need to stratify patient populations to better understand the outcome of enzyme replacement therapy [J].
Germain, Dominique P. .
CLINICAL THERAPEUTICS, 2007, 29 :S17-S18
[8]   Sustained, long-term renal stabilization after 54 months of agalsidase β therapy in patients with Fabry disease [J].
Germain, Dominique P. ;
Waldek, Stephen ;
Banikazemi, Maryam ;
Bushinsky, David A. ;
Charrow, Joel ;
Desnick, Robert J. ;
Lee, Philip ;
Loew, Thomas ;
Vedder, Anouk C. ;
Abichandani, Rekha ;
Wilcox, William R. ;
Guffon, Nathalie .
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2007, 18 (05) :1547-1557
[9]   Fabry disease [J].
Germain, Dominique P. .
ORPHANET JOURNAL OF RARE DISEASES, 2010, 5
[10]   Fabry disease:: Twenty novel α-galactosidase A mutations and genotype-phenotype correlations in classical and variant phenotypes [J].
Germain, DP ;
Shabbeer, J ;
Cotigny, S ;
Desnick, RJ .
MOLECULAR MEDICINE, 2002, 8 (06) :304-310